{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:45:46Z","timestamp":1789764346556,"version":"4.0.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Metachromatic leukodystrophy (MLD) is a rare genetic disorder caused by pathogenic variants of the ARSA gene, leading to a deficiency of the arylsulfatase A enzyme (ARSA) and consecutive accumulation of galactosylceramide-3-0-sulfate in the nervous system. The condition leads to severe neurological deficits and subsequently results in profound intellectual and motoric disability. Especially, the adult form of MLD, which occurs in individuals aged &amp;gt;16 years, poses significant challenges for treating physicians because of the rarity of cases, limited therapeutic options, and different allogeneic hematopoietic cell transplantation (allo-HCT) protocols worldwide. Here, we report the results of allo-HCT treatment in 4 patients with a confirmed adult MLD diagnosis. Bone marrow or mobilized peripheral progenitor cells were infused after a reduced intensity conditioning regime consisting of fludarabine and treosulfan. In 3 patients, allo-HCT was followed by an infusion of mesenchymal cells to further consolidate ARSA production. We observed a good tolerability and an increase in ARSA levels up to normal range values in all patients. A full donor chimerism was detected in 3 patients within the first 12\u00a0months. In a 1-year follow-up, patients with complete donor chimerism showed a neurological stable condition. Only 1 patient with an increasing autologous chimerism showed neurological deterioration and a decline in ARSA levels in the first year. In summary, allo-HCT offers a therapeutic option for reconstituting ARSA enzyme levels in adult patients with MLD, with tolerable side effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011836","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T20:04:52Z","timestamp":1707422692000},"page":"1504-1508","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Allogeneic hematopoietic cell transplantation for adult metachromatic leukodystrophy: a case series"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-7373","authenticated-orcid":false,"given":"Andreas","family":"Riedel","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Faul","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Reuss","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7000-4427","authenticated-orcid":false,"given":"Jan C.","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lang","sequence":"additional","affiliation":[{"name":"2Department I, General Pediatrics, Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-2805","authenticated-orcid":false,"given":"Claudia","family":"Lengerke","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Weissert","sequence":"additional","affiliation":[{"name":"3Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, Tuebingen, Germany"},{"name":"4Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9773-2667","authenticated-orcid":false,"given":"Holger","family":"Hengel","sequence":"additional","affiliation":[{"name":"3Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, Tuebingen, Germany"},{"name":"4Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Gr\u00f6schel","sequence":"additional","affiliation":[{"name":"5Department III, Neuropediatrics, University Children's Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7774-5025","authenticated-orcid":false,"given":"Ludger","family":"Schoels","sequence":"additional","affiliation":[{"name":"3Deutsches Zentrum f\u00fcr Neurodegenerative Erkrankungen, Tuebingen, Germany"},{"name":"4Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-2618","authenticated-orcid":false,"given":"Wolfgang A.","family":"Bethge","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"4","key":"2024032513152966100_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/(SICI)1096-8628(19970905)71:4<475::AID-AJMG20>3.0.CO;2-C","article-title":"Leukodystrophy incidence in Germany","volume":"71","author":"Heim","year":"1997","journal-title":"Am J Med Genet"},{"issue":"1","key":"2024032513152966100_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0030-1253412","article-title":"Metachromatic leukodystrophy--an update","volume":"41","author":"Gieselmann","year":"2010","journal-title":"Neuropediatrics"},{"issue":"9","key":"2024032513152966100_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaneurol.2016.2067","article-title":"Long-term outcome of allogeneic hematopoietic stem cell transplantation in patients with juvenile metachromatic leukodystrophy compared with nontransplanted control patients","volume":"73","author":"Groeschel","year":"2016","journal-title":"JAMA Neurol"},{"key":"2024032513152966100_bib4","volume-title":"GeneReviews","author":"Gomez-Ospina","year":"1993"},{"key":"2024032513152966100_bib5","doi-asserted-by":"crossref","first-page":"576221","DOI":"10.3389\/fmed.2020.576221","article-title":"Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches","volume":"7","author":"Shaimardanova","year":"2020","journal-title":"Front Med"},{"issue":"2","key":"2024032513152966100_bib6","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1212\/WNL.0000000000011047","article-title":"Association of age at onset and first symptoms with disease progression in patients with metachromatic leukodystrophy","volume":"96","author":"Kehrer","year":"2021","journal-title":"Neurology"},{"issue":"12","key":"2024032513152966100_bib7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/acn3.51692","article-title":"Recognizing early MRI signs (or their absence) is crucial in diagnosing metachromatic leukodystrophy","volume":"9","author":"Schoenmakers","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2024032513152966100_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13023-019-1220-4","article-title":"Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective","volume":"14","author":"Beerepoot","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2024032513152966100_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/bmt.2012.155","article-title":"Juvenile metachromatic leukodystrophy 10 years post transplant compared with a non-transplanted cohort","volume":"48","author":"Kr\u00e4geloh-Mann","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2024032513152966100_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"10322","key":"2024032513152966100_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"issue":"6148","key":"2024032513152966100_bib12","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"issue":"1-2","key":"2024032513152966100_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2020.07.002","article-title":"Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: results from a phase 1\/2 clinical trial","volume":"131","author":"\u00ed Dali","year":"2020","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"2024032513152966100_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/acn3.50975","article-title":"Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction","volume":"7","author":"Wolf","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"2024032513152966100_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/jmd2.12221","article-title":"Allogenic hematopoietic stem cell transplantation in two siblings with adult metachromatic leukodystrophy and a systematic literature review","volume":"60","author":"Videb\u00e6k","year":"2021","journal-title":"JIMD Rep"},{"issue":"8","key":"2024032513152966100_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bmt.2010.252","article-title":"Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature","volume":"46","author":"de Hosson","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2024032513152966100_bib17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/bmt.2014.93","article-title":"Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy","volume":"49","author":"Solders","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"2024032513152966100_bib18","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2016-03-708479","article-title":"Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience","volume":"127","author":"van Rappard","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024032513152966100_bib19","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.11802","article-title":"Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report","volume":"93","author":"Meuleman","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"2024032513152966100_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.exphem.2006.06.007","article-title":"In\u00a0vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients","volume":"34","author":"M\u00fcller","year":"2006","journal-title":"Exp Hematol"},{"issue":"3","key":"2024032513152966100_bib21","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.bbmt.2019.12.225","article-title":"High dose hematopoietic stem cell transplantation leads to rapid neural and peripheral disease cross-correction via robust hematopoietic and microglia recovery","volume":"26","author":"Goncalves","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"37","key":"2024032513152966100_bib22","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1073\/pnas.1205858109","article-title":"Brain conditioning is instrumental for successful microglia reconstitution following hematopoietic stem cell transplantation","volume":"109","author":"Capotondo","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2024032513152966100_bib23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.bmt.1703650","article-title":"Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)","volume":"30","author":"Ko\u00e7","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"7-8","key":"2024032513152966100_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/scd.2021.0352","article-title":"Hematopoietic stem cell transplantation with mesenchymal stromal cells in children with metachromatic leukodystrophy","volume":"31","author":"Cabanillas Stanchi","year":"2022","journal-title":"Stem Cell Dev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1504\/2219047\/blooda_adv-2023-011836r2-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1504\/2219047\/blooda_adv-2023-011836r2-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:15:57Z","timestamp":1711372557000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1504\/514870\/Allogeneic-hematopoietic-cell-transplantation-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011836","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]}}}